Articles

The updated efficacy and safety data from the ANCHOR study of melflufen plus dexamethasone and daratumumab or bortezomib in patients with RRMM demonstrated encouraging efficacy that was well-tolerated. Read More ›

Consolidation treatment with bortezomib + lenalidomide + dexamethasone (VRD) followed by lenalidomide maintenance proved superior to lenalidomide maintenance alone in progression-free survival and myeloma response among transplant-eligible patients with NDMM. Read More ›

Induction with ixazomib, daratumumab, and low-dose dexamethasone in frail elderly newly diagnosed multiple myeloma patients in the HOVON 143 study was meaningfully effective regarding ORR and PFS, but with continued toxicity concerns. Read More ›

Melflufen/dexamethasone demonstrated meaningful activity and manageable safety profile in patients with relapsed/refractory multiple myeloma who had ≥2 prior lines of therapy and were also refractory to pomalidomide and/or an anti-CD38 monoclonal antibody. Read More ›

In the DREAMM-2 study of belantamab mafodotin in heavily pretreated relapsed/refractory multiple myeloma patients, comparable overall response rates (~30%) were observed between patients who had 3 to 6 prior therapies and those with ≥7. Read More ›

Addition of venetoclax to bortezomib/dexamethasone in relapsed/refractory multiple myeloma patients (BELLINI phase 3 study) improves progression-free survival, but also results in higher mortality, with t(11;14) or BCL2^high gene expression patients benefiting most. Read More ›

In patients with multiple myeloma who undergo frontline optimized induction followed by ASCT, MRD assessment and clinical response time kinetics were predictive of unsustained complete remission, based on a subgroup analysis of PETHEMA/GEM2012MENOS65. Read More ›

An observational study of ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma in French centers (REMIX) further defined the patient and disease characteristics and safety profile with this regimen; efficacy data are still maturing. Read More ›

This pivotal trial (OPTIMISMM) subgroup analysis supports use of pomalidomide, bortezomib, and low-dose dexamethasone for lenalidomide-refractory patients regardless of age, prior stem-cell transplant status, or presence of high-risk cytogenetic abnormalities. Read More ›

An ongoing study of venetoclax plus daratumumab and dexamethasone ± bortezomib in patients with relapsed/refractory multiple myeloma demonstrated tolerable safety and clinically meaningful overall response rate (92%-96%), particularly among those with t(11;14). Read More ›